Commentary on the Results and Clinical Implications of the PROactive Study
- 1 December 2005
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (12) , 2965-2967
- https://doi.org/10.2337/diacare.28.12.2965
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005
- A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk FactorsArchives of internal medicine (1960), 2004
- Targeting Insulin Resistance and β-Cell Dysfunction: The Role of ThiazolidinedionesDiabetes Technology & Therapeutics, 2004
- ThiazolidinedionesNew England Journal of Medicine, 2004
- The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)Diabetes Care, 2004
- Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factorsCurrent Medical Research and Opinion, 2004
- Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureCirculation, 2003
- A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitusClinical Therapeutics, 2001